Genincode

Genincode Debt/EBITDA

The Total Debt to EBITDA Ratio of Genincode (GENI.L) as of Nov 4, 2026 is -0.02. In the previous year, Total Debt to EBITDA Ratio was -0.05 — a change of -49.32% (higher).

Debt/EBITDA

-0.02

YoY

-49.32%

Last updated:

Total Debt to EBITDA Ratio of Genincode is 2025 -0.02 . Total Debt to EBITDA Ratio of Genincode was 2024 -0.05 . It decreases by -49.32% higher compared to the previous year.

The Genincode Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
-0.66 GBP
Jan 1, 2022
-0.06 GBP
Jan 1, 2023
-0.04 GBP
Jan 1, 2024
-0.05 GBP
Jan 1, 2025
-0.02 GBP
The Genincode Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.02-49.32%
-0.05+11.17%
-0.04-28.75%
-0.06-90.71%
-0.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genincode Stock analysis

What does Genincode do? GENinCode Plc generates revenue through its genetic risk assessment products for cardiovascular disease, including Cardio Incode, Lipid Incode, Sudd Incode, Roca Test, Thrombo, and Thrombo Incode Reproductive Health. The company targets healthcare practitioners who use its genomic precision testing, combining polygenic technology, molecular testing, genotyping, sequencing, and AI bioinformatics to assess patient DNA risk. Its products integrate genetic and clinical data to provide predictive care strategies for cardiovascular disease prevention. The firm serves medical professionals seeking advanced tools for patient risk evaluation and treatment planning. The company's wholly owned subsidiaries, GENinCode S.L.U. and GENinCode U.S. INC., support its global operations in risk assessment and prevention services. GENinCode Plc's focus on cardiovascular disease risk assessment leverages AI-driven bioinformatics to deliver tailored preventative care solutions. Healthcare providers utilize its comprehensive testing suite to enhance clinical decision-making and patient outcomes in cardiovascular health management. Genincode is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genincode stock

Total Debt to EBITDA Ratio of Genincode is -0.02 in 2025.

Total Debt to EBITDA Ratio of Genincode changed from -0.05 to -0.02, representing a -49.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Genincode since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Genincode with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genincode

All Key Metrics — Genincode